Benzinga | Jul 28, 2021 08:04AM EDT

PDS Biotechnology To Present Recent Phase 2 Human Clinical Data And Ongoing Oncology Programs At Investor Conference

PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune(r) T-cell activating technology, announced today that its management team will present at several investor conferences listed below during the third quarter of 2021.



At the recent American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, interim data was presented in an oral session on PDS Biotech's lead asset, PDS0101, in combination with two investigational immune-modulating agents being studied in two groups of advanced cancer patients. In the first group of patients who had failed treatment with chemotherapy and radiation, tumor reduction (objective response) was seen in 83% (5 of 6) of patients. In the second group, patients who in addition had failed treatment with checkpoint inhibitors, tumor reduction was seen in 58% (7 of 12) patients.

PDS0101 (Versamune(r)-HPV16) is an investigational immunotherapy candidate designed to treat cancers caused by infection with HPV16 (HPV16-positive cancers) by activating the immune system to produce in vivo CD8+ (killer) T-cells to target and kill tumors that are HPV16-positive. Analyses of immune responses and other immune correlates are ongoing.

The upcoming investor conferences will offer leadership the opportunity to provide an update on both ongoing PDS0101 Phase 2 clinical trials, as well as preparations to move two other investigational compounds PDS0102 (Versamune(r)-TARP) and PDS0103 (Versamune(r)-MUC1) into human testing. The conference details are as follows:

BTIG Investor Conference

Date: Tuesday, August 10, 2021

HC Wainwright 23rd Annual Global Investment Conference

Date: Tuesday, September 14, 2021

Cantor Healthcare Conference

Date: Monday, September 27, 2021

AGP Fall Virtual Biotech & Specialty Pharma Conference

Date: Wednesday, October 13, 2021

A separate press release will be issued once presentation times become available.